COMPANY
Apros Therapeutics
Apros Therapeutics is a drug discovery and development company focused on tissue-targeted small molecule innate immune agonists to increase tumor immunogenicity – turning cold tumors hot. We do this utilizing chemistry approaches to precisely target the agoni From company website Source · Oct 12, 2026
Timeline
- Trial start Phase 1: A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT04645797 | A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions | Phase 1 | Terminated | Jan 19, 2021 | May 7, 2022 (actual) |